Aneja
Arun Pal Aneja, Digvijaygram IN
Patent application number | Description | Published |
---|---|---|
20110300768 | ETHYLENE ADSORBENT PACKAGING OR BARRIER MATERIAL AND METHOD OF MAKING THE SAME - An ethylene adsorbent packaging or barrier material and method of making the same. The package or barrier comprises a textile substrate impregnated with a solution of zeolite, cross-linker and binder. The method of making the ethylene adsorbent packaging or barrier material comprises impregnating a textile substrate with a solution of zeolite powder with crosslinker and binder in a solvent at a PH of 5.0 to 7.0 adjusted with an organic acid followed by removing the excess solution from the substrate and drying and curing the substrate at 50-250° C. If desired the substrate is formed to the desired shape. The packaging can be used for packing ethylene susceptible and perishable articles. The barrier material can be used as a barrier or as a separator for ethylene gas. | 12-08-2011 |
Arun Pal Aneja, Greenville, NC US
Patent application number | Description | Published |
---|---|---|
20090260707 | Woven Textile Fabric with Cotton/Microdenier Filament Bundle Blend - A fabric includes warp and weft yarns interwoven in a series of repeat units. In the fabric, the warp yarns comprise cotton yarns and the weft yarns comprise microdenier filament bundles. Such a fabric can provide desirable tactile properties for articles such as sheets, pillowcases, blankets and the like. | 10-22-2009 |
Jonathan Paul Aneja, Kirkland, WA US
Patent application number | Description | Published |
---|---|---|
20080320453 | TYPE INFERENCE AND LATE BINDING - A type inference option is available for a computer programming language. The option acts as a switch to specify whether or not type inference is applicable (e.g., on or off). Type inference can be employed in conjunction with late binding or options therefor. In this manner, a computer program can be developed with the convenience of type inference and the flexibility of late binding while still maintaining at a degree of type safety. | 12-25-2008 |
20100218173 | IMPLICIT LINE CONTINUATION - Modified compilers and other development tools provide implied line continuation within a sequence of syntax tokens of a programming language grammar which includes multiple semantic contexts and which uses line termination as presumptive statement termination. When source code parsing encounters a line terminator adjacent a context-dependent implicit line continuation token in an associated semantic context, an explicit decision is made whether to imply line continuation. Line continuation may also be implied in response to other specified tokens. | 08-26-2010 |
Karan Aneja, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20090087891 | METHODS AND DEVICE FOR PRODUCING HYDROGEN FROM BIOMASS - Disclosed herein are methods of producing molecular hydrogen, where the methods comprise contacting a solution comprising urea with a urease to produce ammonia, and contacting the ammonia with a first catalyst to produce a first gaseous mixture comprising molecular hydrogen. | 04-02-2009 |
Manish Kumar Aneja, Munich DE
Patent application number | Description | Published |
---|---|---|
20150126589 | Pulmonary Delivery of Messenger RNA - The invention discloses a method for expressing an mRNA in lung wherein —the mRNA to be expressed is combined with polyethyleneimine (PEI) to provide a combination comprising the mRNA and PEI; —the combination comprising the mRNA and PEI is administered to lung where it enters lung cells; and —the mRNA is expressed in the lung cells. | 05-07-2015 |
Mansi Aneja, Delhi IN
Patent application number | Description | Published |
---|---|---|
20090170603 | Sports community commentary - Live sports community commentary technology operable to provide viewers with live sports commentary, and provide commentators with a means to provide commentary to viewers is disclosed. The live sports community commentary technology presents commentary from commentators on a sports event to viewers of the sports event, and provides feedback, motivation, and incentives to the commentators. | 07-02-2009 |
Nagender Aneja, Brunei BN
Patent application number | Description | Published |
---|---|---|
20150339657 | Anti-fraud computer implemented method for financial card transaction - A computer implemented method for a financial transaction via a financial card which by default is in blocked state is described. The method comprises receiving a request in form of a message to unblock the financial card for a predetermined duration. The request is received from an electronic communicating device (ECD) by a financial institution server (FIS). The electronic communicating device has a number wherein the number is registered with the financial card. On receiving the request, the financial institution server verifies the request and genuineness of the user and after verification authorizes the request and the financial card gets unblocked for the predetermined duration. | 11-26-2015 |
Priyam Aneja, New Delhi IN
Patent application number | Description | Published |
---|---|---|
20150066803 | QUANTITATIVE PRODUCT FEATURE ANALYSIS - Providing product review related information to a product review user by: (i) determining a plurality of products having a common product type; (ii) determining a plurality of product features of the plurality of products of the common product type; and (iii) determining, independently of any input from the product review user, a plurality of feature clusters, with each feature cluster including at least two features of the plurality of product features. This software-defined clustering of product features can help review users find the most suitable products and/or services. | 03-05-2015 |
20150066806 | QUANTITATIVE PRODUCT FEATURE ANALYSIS - Providing product review related information to a product review user by: (i) determining a plurality of products having a common product type; (ii) determining a plurality of product features of the plurality of products of the common product type; and (iii) determining, independently of any input from the product review user, a plurality of feature clusters, with each feature cluster including at least two features of the plurality of product features. This software-defined clustering of product features can help review users find the most suitable products and/or services. | 03-05-2015 |
Rajindra Aneja, Ithaca, NY US
Patent application number | Description | Published |
---|---|---|
20110040108 | INOSITOLPHOSPHOLIPIDS AND ANALOGUES PHOSPHATIDYLINOSITOL PRODUCTS AND PROCESSES - Embodiments of the invention relate to natural and synthetic inositolphospholipid (IPL) materials, their preparation and applications. They provide compositions of the parent IPL comprising phosphatidylinositol (PI), PI-phosphates (phosphoinositides) and derivatives and analogues, and a process for their production starting from natural IPL. The embodiments further provide functional derivatives of PI for biomedical applications including a platform for drug design and delivery to therapeutic targets in the phosphoinositide mediated cellular signaling and allied cascades. The embodiments pertain to IPL having absolute stereo-structure. The embodiments further pertain to unique IPL and PI product compositions for defined applications, particularly pharmaceutical compositions for prophylaxis and treatment of diseases related to aberrant cellular and nuclear signaling mediated by PI and PI derived phosphates, and associated phosphoinositide specific enzymes including PI-PLC and PI 3-kinase. | 02-17-2011 |
Rakesh Aneja, Farmington Hills, MI US
Patent application number | Description | Published |
---|---|---|
20080314033 | Treatment of diesel engine exhaust - A diesel exhaust treatment system for treating exhaust gas from a diesel engine comprises at least one diesel particulate filter, at least one diesel exhaust fluid mixing chamber and at least one selective catalytic reduction converter (SCR). In one desirable embodiment, plural diesel particulate filters are arranged in parallel and plural SCRs are arranged in parallel. These components including the diesel exhaust fluid mixing chamber can be included in a common housing with the exhaust flow reversing directions a plurality of times as it passes through the treatment system from an exhaust inlet to an exhaust outlet. The housing can be coupled to one vehicle frame rail with most of the housing and components contained therein positioned outside the outer surface of the one frame rail. | 12-25-2008 |
20120260635 | TREATMENT OF DIESEL ENGINE EXHAUST - A diesel exhaust treatment system for treating exhaust gas from a diesel engine comprises at least one diesel particulate filter, at least one diesel exhaust fluid mixing chamber and at least one selective catalytic reduction converter (SCR). In one desirable embodiment, plural diesel particulate filters are arranged in parallel and plural SCRs are arranged in parallel. These components including the diesel exhaust fluid mixing chamber can be included in a common housing with the exhaust flow reversing directions a plurality of times as it passes through the treatment system from an exhaust inlet to an exhaust outlet. The housing can be coupled to one vehicle frame rail with most of the housing and components contained therein positioned outside the outer surface of the one frame rail. | 10-18-2012 |
Rakesh K. Aneja, Novi, MI US
Patent application number | Description | Published |
---|---|---|
20130067890 | METHOD OF OPTIMIZING OPERATING COSTS OF AN INTERNAL COMBUSTION ENGINE - A method to optimize operation of a diesel fuel engine having at least one aftertreatment device to reduce NOx is provided. An electronic control unit for a diesel engine with an aftertreatment device for the reduction of NOx is also provided. The method and the control unit optimize a quantity of fuel to be injected into an aftertreatment device based upon inputs relating to the cost of diesel fuel and the cost of diesel exhaust fluid. | 03-21-2013 |
Ritu Aneja, Lilburn, GA US
Patent application number | Description | Published |
---|---|---|
20100227878 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. Representative analogs include the 9-nitro, 9-bromo-, 9-iodo-, and 9-fluoro-noscapines, which bind tubulin and induce apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. Surprisingly, treatment with one of the analogs, 9-nitro-nos, at doses as high as 100 μM, did not affect the cell cycle profile of normal human fibroblasts. This selectivity for cancer cells represents a unique edge over the other available antimitotics. The compounds can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, the compounds are novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 09-09-2010 |
20110286919 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER - The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine framework. Pharmaceutical compositions including the compounds, and methods of treating various tumors using the compounds and compositions, are also disclosed. The conjugates are particularly useful for treating cancers which overexpress the Folate Receptor α (FRa) receptor. | 11-24-2011 |
20110294844 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 12-01-2011 |
20130150332 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 06-13-2013 |
20130224310 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. While the antitussive plant alkaloid, noscapine, binds tubulin, displays anticancer activity, and has a safe pharmacological profile in humans, structure-function analyses pointed to a proton at position 9 of the isoquinoline ring that can be modified without compromising tubulin binding activity. Noscapine analogs with various functional moieties at position 9 on the isoquinoline ring kill human cancer cells resistant to other anti-microtubule agents, such as vincas and taxanes. | 08-29-2013 |
20140121233 | Synthesis and Characterization of Second Generation Benzofuranone Ring Substituted Noscapine Analogs - Compound of Formula (I) and use thereof as microtubule modulating agents in the treatment of cancer are described herein. | 05-01-2014 |
20150160222 | COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF CANCER - A method of diagnosing and/or treating a patient diagnosed with breast cancer includes the steps of: (a) identifying a patient as having a triple negative breast cancer; (b) obtaining a sample from the triple negative breast cancer patient comprising breast cancer cells; and (c) determining whether the cells in the sample express an elevated level of nuclear HSET, wherein an elevated level indicates a poorer prognosis. The method may further include the step of determining whether the cells in the sample express elevated level(s) of one or more products upregulated with HSET, elevated levels of phosphorylated histone-H3 and/or exhibit enhanced Cdk1 activity. In certain embodiments, the method further includes the step of administering one or more therapeutic agents, such as HSET inhibitors, centrosome declustering agents, PARP inhibitors, Ras/MAPK pathway inhibitors, PI3K/AKT/mTOR pathway inhibitors or a combination thereof. | 06-11-2015 |
20150248523 | METHOD FOR DETERMINING THE RISK PROFILE OF NEOPLASTIC TISSUE - A method of computing the risk profile of a neoplastic tissue in a patient is disclosed. The method includes the steps of (a) processing a sample of tumor tissue or cancer cells from the patient in a form suitable for visualization and demarcation of cell nuclei, individually distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs) in a region of interest (ROI) defined by a plurality of cell nuclei; (b) determining the numbers of iCTRs and mCTRs associated with each cell nucleus in the ROI; (c) determining the volume of each iCTR and mCTR in the ROI; and (d) calculating one or more centrosome amplification scores (CASs) values for the sample based on steps (b) and (c), wherein the one or more CASs indicate the severity of centrosome amplification, the frequency of centrosome amplification, or both, and wherein the one or more scores provide a measure of a level of risk and/or a prognosis associated with the neoplastic tissue. | 09-03-2015 |
20150309031 | COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF CANCER - A method of diagnosing and/or treating a patient diagnosed with breast cancer includes the steps of: (a) identifying a patient as having a triple negative breast cancer; (b) obtaining a sample from the triple negative breast cancer patient comprising breast cancer cells; and (c) determining whether the cells in the sample express an elevated level of nuclear HSET, wherein an elevated level indicates a poorer prognosis. The method may further include the step of determining whether the cells in the sample express elevated level(s) of one or more products upregulated with HSET, elevated levels of phosphorylated histone-H3 and/or exhibit enhanced Cdk1 activity. In certain embodiments, the method further includes the step of administering one or more therapeutic agents, such as HSET inhibitors, centrosome declustering agents, PARP inhibitors, Ras/MAPK pathway inhibitors, PI3K/AKT/mTOR pathway inhibitors or a combination thereof. | 10-29-2015 |
20150346191 | COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF NEOPLASM - A protocol for assessing the prognosis for a patient diagnosed with a neoplasm or suspected of having a neoplasm is provided herein. The protocol involves the steps of determining a mitotic cells to proliferating cells ratio (M:P ratio) in a neoplastic tissue sample obtained from the patient and producing a prognosis for the neoplasm based on the M:P ratio. | 12-03-2015 |
Ritu Aneja, Liburn, GA US
Patent application number | Description | Published |
---|---|---|
20160022753 | COMPOSITIONS DERIVED FROM SWEET POTATO GREENS AND METHODS OF PREPARATION AND USE - The present invention includes methods of identifying a fraction of a sweet potato greens extract (SPGE) that is useful in reducing the risk of or treating, cancer, hypertension, diabetes, or a wound; compositions including the identified fraction(s); methods of administering SPGEs or fractions thereof; and uses of the compositions described herein in the preparation of a medicament. | 01-28-2016 |
Sandhya Aneja, Brunei BN
Patent application number | Description | Published |
---|---|---|
20150339657 | Anti-fraud computer implemented method for financial card transaction - A computer implemented method for a financial transaction via a financial card which by default is in blocked state is described. The method comprises receiving a request in form of a message to unblock the financial card for a predetermined duration. The request is received from an electronic communicating device (ECD) by a financial institution server (FIS). The electronic communicating device has a number wherein the number is registered with the financial card. On receiving the request, the financial institution server verifies the request and genuineness of the user and after verification authorizes the request and the financial card gets unblocked for the predetermined duration. | 11-26-2015 |
Vipul Aneja, Redmond, WA US
Patent application number | Description | Published |
---|---|---|
20140075372 | POINTER UNIFICATION - Embodiments relate to a computing device having storage, a processor, a display, a first human input device, and a second human input device, where the first human input device is in a first category of human input devices and the second human input device is in a second category of human input devices. The computing device may perform a process involving executing a windowing environment that manages windows of applications executing on the computing device. The windowing environment may receive raw inputs from the first and second human input devices and in turn generate input pointers for the raw inputs, respectively. The input pointers may be or include instances of an input pointer class implemented by the windowing environment, the pointer class used by the windowing environment for arbitrary different types of human input pointer devices including the first human input device and the second human input device. | 03-13-2014 |